InCarda Therapeutics

InCarda Therapeutics, Inc. is a private, clinical-stage biopharmaceutical company pioneering a novel approach to treating cardiovascular diseases via the inhaled route. The drug's advantage lies in providing the “first pass” of medicine directly to cardiac tissue, delivering a small but effective dose precisely to the affected area of the heart. This allows for rapid onset of the drug, reduced off-target tissue exposure, lower sustained/prolonged exposure to cardiac tissue, and more importantly, patients can self-administer the treatment wherever a PAF episode may occur.The lead product under development is an inhaled therapy for the treatment of paroxysmal atrial fibrillation (PAF), a prevalent form of atrial arrhythmia. InCarda adopts a risk-mitigated approach by repurposing approved drugs with long-term efficacy and safety in a new dosing paradigm.